ESMO 2024: Positive pooled data from Nuvation Bio highlight taletrectinib benefits

14 September 2024

New York-based Nuvation Bio (NYSE: NUVB) today announced positive pooled data from the pivotal Phase II TRUST-I and TRUST-II studies of taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) for the treatment of patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

The data were presented at the European Society of Medical Oncology (ESMO) Congress 2024, now taking place in Barcelona, Spain.

The ROS1 inhibitor landscape has seen significant advancements, though there is still an unmet need for more durable and tolerable treatment options for patients. Nuvation Bio’s data showed compelling response rates and prolonged progression-free survival (PFS), highlighting taletrectinib’s best-in-class potential to address this unmet need.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK